CLYM Eliem Therapeutics, Inc. Insider Trading

RA Capital Management purchased 7,111 shares of CLYM at $3.50 on 2026-01-05, growing position to 3,403,429 shares amid unprofitable fundamentals.

RA Capital Management acquired 7,111 shares at $3.50, a relatively small incremental addition to an already substantial 3.40M-share position, at a price 16.7% below the current market price of $4.20. The purchase follows two prior buys at the same ticker within days (2025-12-11 and 2025-12-12), suggesting repeated accumulation despite Climb Bio's unprofitable fundamentals—the company reported a net loss of $12.9M over its most recent full fiscal year. The stock has recovered sharply (+132.0% over 30 days, +122.2% over 90 days) from a 52-week low of $1.13, yet remains -14.8% from its 52-week high of $4.93. The insider's broader cross-ticker history shows 2 prior buys against 18 prior sells with a modest +4.5% average 30-day return following sales, which does not establish a strong pattern of timing acumen at this specific ticker.

Director RA Capital Management purchases 314,561 shares in 2 tranches at $2.18–$2.86; stock now at $3.81, up 100.5% in 30 days.

RA Capital Management, a Director, executed 2 separate purchases totaling 314,561 shares for $754,737.14 at prices ($2.18 and $2.86) well below the current price of $3.81, expanding holdings by 10.2% to 3,396,318 shares. The timing coincides with exceptional recent momentum: the stock has rallied 100.5% over the prior 30 days and 89.6% over 90 days, now sitting at its 52-week high. However, this purchase occurs against a backdrop of ongoing unprofitability ($-12,888,000.00 net income) and the insider's cross-ticker track record shows 20 prior sells with no offsetting buys recorded in the summarized history. The filing reflects a director's discretionary accumulation during a period of sharp stock appreciation, warrant deeper examination into whether this represents conviction in the company's turnaround or a specific investment thesis distinct from the broader momentum.

EVP R&D at ELYM dumps 129.2K shares (80.5% of holdings) across 4 sales at $7.09–$8.07 as stock near 52-week high

Valerie Morisset, EVP of R&D and CSO, executed 4 separate sales totaling 129,206 shares for $988,495.44 between July 19–22, 2024, reducing her holdings from 160,523 shares to 31,317 shares. The sales were concentrated near the company's recent price range, with transactions at $7.09, $7.24, $8.07, and $7.98—all trading near the current price of $8.93 and within the 52-week high of $10.20. The magnitude of the liquidation (80.5% of pre-transaction holdings) in a biotech company that reported a full-year net loss of $-1,697,000.00 is notable and reflects a substantial reduction in her equity stake. The pattern of five consecutive daily sells at this ticker from July 9–15 (followed immediately by the filing of these four additional sales) suggests intentional and deliberate execution rather than a single rebalancing event, warranting attention from investors monitoring insider conviction levels in an unprofitable stage-gate research company.

EVP Valerie Morisset sold 92,377 shares at blended $7.04 (totaling $650.6K) in two transactions on 2024-07-12 and 2024-07-15.

Valerie Morisset, EVP of R&D and CSO, executed two separate open-market sales totaling 92,377 shares for $650,562.77, reducing her holdings by 26.8% from 344,683 to 252,306 shares. The stock has declined 19.9% over 30 days and is trading 30.8% below its 52-week high of $10.20, suggesting a weakening price environment at the time of sale. Eliem Therapeutics remains unprofitable with net income of $-1,697,000.00 for its most recent full fiscal year, which adds context to insider liquidity activity. The two separate sales within a narrow 3-day window (July 9–15, with measurable sales on July 12 and July 15) represent a material reduction in executive equity exposure at a time of declining stock momentum and negative earnings.

EVP R&D Valerie Morisset sold 105,931 shares in 3 transactions for $736,500.46; company unprofitable with -$1.7M net income.

Valerie Morisset, EVP of R&D and Chief Scientific Officer, executed 3 separate sales totaling 105,931 shares for $736,500.46 (blended average $6.95 per share) over July 9–11, 2024, reducing her holdings by 23.5% from 450,614 to 344,683 shares. The sales occurred near the 52-week high region (current price $7.07 is only -30.7% from the $10.20 peak) and amid positive recent momentum (+64.0% over 90 days), yet the company remains unprofitable with net income of -$1,697,000.00. The coincidence of a material reduction in the R&D leadership's stake during a loss-making period, while the stock trades near highs, warrants close attention to whether R&D headwinds, pipeline setbacks, or capital constraints are driving the divestiture.

RA Capital Management bought 13,008,546 shares (13.01M) at $3.84 for $49,952,816.64 ($50.0M) in 2 transactions on 2024-06-27.

RA Capital Management, a director at unprofitable Eliem Therapeutics, executed 2 separate purchases totaling 13,008,546 shares (13.01M shares) for $49,952,816.64 ($50.0M) at $3.84 on 2024-06-27. The company is currently trading at $7.05, up 150.9% over the past 90 days from this insider's purchase date, though down 30.9% from its 52-week high and down 8.6% over the past 30 days. Across RA Capital Management's open-market history (20 prior buys across all tickers), the insider's average 90-day return has been -3.1% with a 42.11% win rate, indicating mixed outcomes. The substantial dollar volume ($50.0M) and share magnitude (13.01M shares) in a single filing, combined with the company's negative net income of $-1.7M, merit investor attention to the underlying investment thesis and timing context.